12ACTIVITIES
1ORGS REPRESENTED
36BILLS
Organizations represented
1Orgs whose LD-2 filings list Hansjorg as an active lobbyist, sorted by activity volume.
Bills they file on
36H.R. 16726 mentions
H.R. 9466 mentions
H.R. 12625 mentions
S. 10974 mentions
H.R. 14924 mentions
S. 5274 mentions
S. 10964 mentions
S. 8643 mentions
S. 10953 mentions
S. 26583 mentions
S. 10413 mentions
S. 5262 mentions
S. 7052 mentions
S. 20822 mentions
S. 9462 mentions
+ 21 more bills referenced in their activities
Topics in Filings
294Policy topics Hansjorg files on across all their LD-2 activities.
BIOSECURE Act×21
Interagency Patent Coordination and Improvement Act×21
Preserve Access to Affordable Generics and Biosimilars Act×19
House GOP RFI on Supply Chain×17
Bio COMPETES×16
Show all 294 topics (+289 more) ▾
Prescription Pricing for the People Act×16
National Coverage Determination×14
Stop STALLING Act×13
FY 2025 Appropriations×13
ORPHAN Cures Act×12
Pharmacy Benefit Manager Transparency Act×12
CMMI Authority×12
Affordable Prescriptions for Patients Act×10
Restrictions on Intellectual Property Rights×10
Maintaining Investments and New Innovation×9
FY 2026 Appropriations×8
Value-Based Purchasing×8
Monoclonal Antibody Coverage and Utilization×8
Vaccine Injury Compensation Program×8
Medication Affordability and Patient Integrity Act×7
Prohibiting Adversarial Patents Act×7
Clinical Trial Data in China×7
Mandating Exclusive Review of Individual Treatments×7
American Privacy Rights Act×6
Bill to address patent thickets×6
Patent Eligibility Restoration Act×6
Executive Order on Access to Affordable Life-Saving Medications×6
Interchangeability and Pharmacy Substitution×6
Promising Pathway Act×6
Quality & Distribution×6
Advanced Manufacturing×6
Drug Shortages×6
Supply Chain Integrity and Traceability×6
Patient Cost-Sharing and Implementation×6
Strengthening Innovation in Medicare and Medicaid Act×6
Alternative Payment Arrangements for Gene Therapies×6
Drug Benefit Design×6
National Defense Authorization Act×6
SUPPORT Act×6
Adult Immunization×6
MCM Manufacturing & Capacity×6
MCM PRV Reauthorization×6
Vaccine Safety net and Vaccine Infrastructure×6
Value of Vaccines and Vaccine Confidence×6
Antimicrobial Resistance×6
Drug Pricing×6
Biosimilar Red Tape Elimination Act×6
Lowering Drug Costs for American Families Act×6
SAFE STEP Act×6
CICP×5
Biosimilar Copay×5
Safe, and Secure American Bioeconomy×5
Patent Thickets×5
COVID-19 Pricing Related Provisions×5
Coverage of Accelerated Approval Products×5
Pricing and Rebates×5
Give Kids a Chance Act×5
Drug Supply Chain Management×5
Supply Chain Issues×5
HELP Copays Act×5
Medicare Part B Physician-Administered Products×5
Patient Cost-Sharing and Smoothing×5
Support of Patient Premiums and Cost-Sharing Obligations×5
Maternal Immunization×5
VICP Loopholes×5
Program Implementation & Oversight×5
Vaccines and Infectious Diseases×5
Access to Innovative Treatments Act×5
Medicare Drug Price Negotiation Act×5
Modernizing and Ensuring PBM Accountability×5
Prescription Drug Price Relief Act×5
Bayh-Dole Act×4
Drug Patenting×4
FTC Orange Book Delisting Initiative×4
China Patent Reform×4
Section 101 Modernization×4
Accelerated Approval Artificial Intelligence×4
Development and Procurement Issues×4
MCM PRV Program Reauthorization×4
WHO Pandemic Preparedness Accord Biosimilars×4
Decentralized Clinical Trials×4
PBM Reform×4
Development and Procurement×4
Funding for Strategic National Stockpile×4
Average Manufacturer Price Calculations×4
Pediatric Priority Review Voucher Program×4
Temporarily Refundable R&D Credit×4
WHO Pandemic Preparedness Accord×4
Lower Costs×4
Protected Classes×4
Vaccine and Antimicrobial Resistance Product Development and Incentives×4
340B Accountability Act×4
Orphan Drug Tax Credit×4
Alternative Funding Programs×4
PROTECT 340B Act×4
Most Favored Nation×4
Medicaid VBPs for Patients×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
Pharmacy Benefit Managers Artificial Intelligence×3
PTO Proposed Rules on Terminal Disclaimer Practice×3
Patent Litigation Reform×3
Genetic Resources, and Associated Traditional Knowledge×3
TRIPS Waiver×3
Risky Research Review Act×3
Reasonable Pricing Clauses in BARDA Contracts×3
Tropical Disease Priority Review Voucher×3
Reimbursement Cell & Gene Therapy×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
FDA Hiring Flexibility Drug Importation Drug Manufacturing×3
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×3
Non-Opioid Analgesics×3
R&D Funding for Medical Countermeasures×3
Medical Countermeasures PRV Reauthorization×3
Administration Rebate Rule×3
Value-based Contracting and Communications×3
Countermeasures Injury Compensation Program×3
Vaccine Safety and Quality×3
ETHIC Act×3
FY 2026 Appropriations for Agencies×3
ASPR×3
Centers for Disease Control and Prevention×3
Health Resources and Services Administration×3
HHS Office of Infectious Disease and HIV/AIDS Policy×3
Biodefense/Biomedical/Emergency Preparedness Research×3
Creating Hope Reauthorization×3
Influenza Planning & Response×3
Pandemic Preparedness×3
PPRV×3
Prescription Drug User Fee Act×3
Project Bioshield×3
SUSTAIN 340B Act×3
Emerging New Threats and×3
FDA Hiring Flexibility×3
DRUG Act×3
Increasing Transparency in Generic Drug Application×3
Medicare Negotiation and Competitive Licensing Act×3
FDA Modernization×3
Act 3.0 Medicaid×3
Orphan Drug Issues×3
Innovation in Pediatric Drugs Act×3
Retaining Access and Restoring Exclusivity×3
Step Therapy×3
Let Injured Americans Be Legally Empowered×3
MCM R&D Incentives×3
Vaccine Injury Compensation Modernization×3
Vaccine Quality Measure×3
Vaccine Safety×3
Reasonable Pricing Clause Compulsory Licensing Data Privacy×2
Inventor Diversity for Economic Advancement×2
Orange Book Listing×2
Protecting Americans Data from Foreign Adversaries Act×2
World Health Organization×2
Treaty on Intellectual Property×2
340B Drug Discount Program×2
NDAA×2
MINI Act×2
Climate Change×2
Diversity & Inclusion×2
Medicaid Drug Rebate Program Rule×2
Coverage and Reimbursement Orphan Drug Issues×2
Orphan Drug Tax Credit Pandemic Preparedness×2
More Cures Act×2
BSUFA Negotiations×2
Compounded Medicines Drug Patenting×2
Medicaid Drug Rebate Program×2
Patenting of Biological Inventions×2
Funding for Women's Health Research×2
Disease X Act×2
Gain of function×2
SAFE Risky Research Act×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
Fair Prescription Drug Prices for Americans Act×2
Global Fairness in Drug Pricing Act×2
More Transparency Act×2
Vaccine Access Improvement Act×2
Family Vaccine Protection Act×2
Dept of Commerce Patent Valuation Fee Proposal×2
Big Savings Act×2
World Intellectual Property Office×2
Pandemic Preparedness -R&D Funding for Medical Countermeasures×2
National Defense Authorization Act 2026×2
One Big Beautiful Bill Act×2
Generic Drug Entry×2
Generic Drug Application Review Reforms×2
Incentives for Generic Entry Issues×2
CFIUS and Foreign Investment Drug Importation Drug Pricing×2
Foreign Drug Data Protection Laws×2
China Synthetic Biotech Tariffs Trade Relations×2
Section 232×2
China Biotechnology Regulations×2
Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1
Invent Here×1
Make Here Act×1
March-In Rights×1
Title 35 to Address Infringements of Patents Claiming Biological Products×1
Protecting Consumer Access to Generic Drugs Act×1
USPTO Request for Comments: Experimental Use Defense 89 Fed×1
Reg 53963 Patenting of Biological Inventions×1
RESTORE Patent Rights Act×1
WHO Pandemic Preparedness Accord World Intellectual Property Office×1
Program & Oversight×1
Biosecurity Infrastructure for Operational×1
American Pandemic Preparedness Plan×1
White House National Biodefense Strategy×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
Compounded Medicines×1
MCM PRV×1
VICP×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
FY 2026 Appropriations Funding for National Institutes of Health×1
Advanced Research Projects Agency for Health×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Innovation and Pediatric Drugs Act×1
March-In Rights Compulsory Licensing Data Privacy×1
Foreign Drug Data Protection Law×1
National Institute of Health×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Coverage and Reimbursement×1
Rare Disease Pilot Program Pandemic Preparedness×1
Project Bio Shield×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
Countermeasure Injury Compensation Fund Amendment Act×1
VICP CICP×1
Pharmacy Benefit Managers×1
General Artificial Intelligence×1
March-In Rights Data Privacy×1
Skinny Labels×1
Patent Tax/fees Foreign Drug Data Protection Law×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
FY 2026 Appropriations for Specific Issues×1
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×1
Biosimilars Red Tape Elimination Act×1
Cell & Gene Therapy×1
Decentralized Clinical Trials Drug Evaluation and Review×1
Prescription Drug Pricing for the People Act×1
Most Favored Nation Foreign Drug Data Protection Laws×1
Non-Opioid Analgesics Orphan Drug Issues×1
Medical Countermeasure Priority Review Voucher Reauthorization×1
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×1
Reference Pricing in Drug Reimbursement×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
B5 Coalition on Supply Chain Resiliency×1
Patent Tax/fees×1
Intellectual Property Enforcement×1
National Institutes of Health FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program×1
Vaccine Injury Compensation Program 340B Drug Discount Program×1
340B ACCESS Act×1
State Strategic Stockpile Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Compounding Pharmacies×1
Contract Manufacturing Ecosystem in the United States×1
Biologics Competition Act×1
Most Favored Nation Drug Pricing Proposals×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Access to Innovative Treatments×1
Administrative Rebate Rule×1
PASTEUR ACT×1
CMMI Models×1
Intellectual Property International Enforcement×1
Bilateral Trade Negotiations×1
US-China IP Provisions×1
Word Health Organization×1
Pulled from the org’s own LD-2 disclosures. See the source filings ↓
Issue mix
LDA general-issue codes weighted by activity count.
Copyright/Patent/Trademark4
Health Issues4
Medicare/Medicaid2
Trade (domestic/foreign)2